세계의 저밀도 지단백질 검사 시장 보고서(2025년)
Low-Density Lipoprotein Test Global Market Report 2025
상품코드 : 1821684
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

저밀도 지단백질 검사 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 5.4%를 나타낼 것으로 예측되고 109억 1,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 의료비 지출 증가, 인구 고령화, 심혈관 질환 부담 증가, 맞춤형 의약품으로의 전환, 의료 정책 및 지침 강화 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 심혈관 질환 유병률 증가, 예방 의료 및 맞춤형 의약품·치료 강조, 건강 인식 및 교육 주력, 규제 지침 및 권고사항 등이 포함됩니다.

향후 5년간 5.4% 성장 전망은 이전 예측 대비 0.2% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 영향 때문입니다. 무역 긴장은 스웨덴과 캐나다에서 개발된 직접 저밀도 지단백 콜레스테롤(LDL-C) 분석법 및 지단백 전기영동 시스템의 가격을 상승시켜 미국 예방 심장학 발전을 저해할 수 있으며, 이는 심혈관 위험 평가 지연과 실험실 검사 비용 증가로 이어질 수 있습니다. 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 인해 그 영향은 더욱 광범위하게 될 것입니다.

심혈관 질환의 유병률 증가는 향후 수년간 저밀도 콜레스테롤(LDL) 검사 시장의 성장을 가속할 것으로 예측됩니다. 심혈관 질환은 심장과 혈관에 영향을 미치는 질환입니다. 심혈관 질환은 심장이나 혈관에 영향을 미치는 질환입니다. LDL 검사는 체내 저밀도 지단백 수치를 직접 측정하여 심혈관 질환을 관리하는 데 사용됩니다. 예를 들어, 2024년 2월 영국 의회(영국 통치 기관)는 심장 및 순환기 질환이 잉글랜드 전체 사망의 약 25%를 차지하며, 연간 14만 명 이상, 하루 약 480명(3분마다 1명)의 사망을 초래한다고 보고했습니다. 결과적으로 심혈관 질환의 증가하는 유병률은 LDL 검사 수요를 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

The low-density lipoprotein (LDL) test is a blood test employed by doctors to measure a patient's levels of LDL cholesterol in the bloodstream. This testing can evaluate LDL levels independently or as part of a lipid panel test, offering insights into the accumulation of cholesterol in the arteries, which can contribute to heart attacks and strokes.

The primary product types of low-density lipoprotein tests include LDL-C, LDL-P, LDL-B, and other related products. Low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol,' tends to accumulate in the walls of blood vessels, increasing the risk of health issues such as heart attacks or strokes. The components used in these tests include kits, reagents, devices, and other related components. These tests find applications in various health conditions such as diabetes, stroke, atherosclerosis, obesity, dyslipidemia, carotid artery disease, peripheral arterial disease, angina, among others. Distribution channels encompass direct tenders and retail outlets, with usage prevalent in hospitals, clinics, ambulatory care centers, research laboratories, and other healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The low-density lipoprotein test market research report is one of a series of new reports from The Business Research Company that provides low-density lipoprotein test market statistics, including low-density lipoprotein test industry global market size, regional shares, competitors with a low-density lipoprotein test market share, detailed low-density lipoprotein test market segments, market trends and opportunities, and any further data you may need to thrive in the low-density lipoprotein test industry. This low-density lipoprotein test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The low-density lipoprotein test market size has grown steadily in recent years. It will grow from $8.52 billion in 2024 to $8.83 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to research advancements in cardiovascular medicine, increased awareness of heart health, shift in treatment paradigms, clinical guidelines and recommendations, focus on preventive healthcare.

The low-density lipoprotein test market size is expected to see strong growth in the next few years. It will grow to $10.91 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to increasing healthcare expenditure, aging population demographics, rise in cardiovascular disease burden, shift towards personalized medicine, healthcare policy and guidelines. Major trends in the forecast period include rising cardiovascular disease prevalence, emphasis on preventive healthcare, personalized medicine and treatment, focus on health awareness and education, regulatory guidelines and recommendations.

The forecast of 5.4% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. preventive cardiology by inflating prices of direct Low-Density Lipoprotein Cholesterol(LDL-C) assays and lipoprotein electrophoresis systems developed in Sweden and Canada, resulting in delayed cardiovascular risk assessment and higher laboratory testing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the low-density lipoprotein (LDL) test market in the coming years. Cardiovascular diseases are conditions that affect the heart or blood vessels. The LDL test is used to manage cardiovascular diseases by directly measuring the levels of low-density lipoprotein in the body. For example, in February 2024, the UK Parliament, the governing body of the UK, reported that heart and circulatory diseases are responsible for around 25% of all deaths in England, causing over 140,000 fatalities annually and approximately 480 deaths per day, or one death every three minutes. As a result, the growing prevalence of cardiovascular diseases is boosting the demand for LDL tests.

The increasing prevalence of obesity is expected to fuel the growth of the low-density lipoprotein test market. Obesity, characterized by excessive body fat accumulation and a body mass index (BMI) of 30 or higher, is associated with numerous health risks. The low-density lipoprotein (LDL) test is instrumental in measuring LDL cholesterol levels in individuals affected by obesity. For instance, according to the World Health Organization's March 2022 report, over 1 billion individuals globally grapple with obesity, comprising 650 million adults, 340 million adolescents, and 39 million children, with these numbers on the rise. Additionally, it is estimated that around 167 million people are poised to experience compromised health due to being overweight or obese. Therefore, the increasing prevalence of obesity is propelling the growth of the low-density lipoprotein test market.

Product innovations are becoming increasingly popular in the low-density lipoprotein (LDL) test market. Leading companies in this sector are launching innovative products to maintain their market positions. For example, in July 2023, Numares Health, a diagnostic company based in Germany, introduced the AXINON LDL-p Test System. This FDA-approved diagnostic tool offers a more comprehensive analysis of lipoproteins, providing insights into cardiac function that go beyond traditional LDL-C measurements. The system uses nuclear magnetic resonance (NMR) spectroscopy and advanced diagnostic algorithms to improve accuracy. It aids physicians in managing patients with a high risk of cardiovascular disease, especially those with cardiometabolic risk factors.

In February 2023, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, completed the acquisition of CinCor Pharma Inc. for an undisclosed amount. This strategic move is expected to bolster AstraZeneca's cardiorenal pipeline, expanding it with Baxdrostat, a novel aldosterone synthase inhibitor (ASI). CinCor Pharma Inc., a US-based clinical-last biotechnology company, specializes in developing therapies for lowering LDL hypertension.

Major companies operating in the low-density lipoprotein test market include Abbott Laboratories, Qiagen N.V., Randox Laboratories Ltd., Eurofins Scientific SE, Danaher Corporation, Bio-Rad Laboratories Inc., OPKO Health Inc., DiaSorin S.p.A., Boster Biological Technology Ltd., Rockland Immunochemicals Inc., Sekisui Diagnostics LLC, DiaSys Diagnostic Systems GmbH, Eurolyser Diagnostica GmbH, Diazyme Laboratories Inc., Cell Biolabs Inc, Home Access Health Corporation, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Quest Diagnostics Incorporated, SpectraCell Laboratories Inc., Siemens Healthineers, Laboratory Corporation of America Holdings, Merck KGaA, F Hoffmann-La Roche Ltd., Agilent Technologies Inc., BioVision Incorporated, Abcam plc, BioAssay Systems, BioChain Institute Inc., BioLegend Inc., Enzo Life Sciences Inc., GenScript Biotech Corporation

North America was the largest region in the Low-Density Lipoprotein Test market in 2024. The regions covered in the low-density lipoprotein test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the low-density lipoprotein test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The low-density lipoprotein test market includes revenues earned by entities by measuring very low-density lipoprotein (VLDL) testing and ultra low-density lipoprotein (ULDL) testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Low-Density Lipoprotein Test Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on low-density lipoprotein test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for low-density lipoprotein test ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The low-density lipoprotein test market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Low-Density Lipoprotein Test Market Characteristics

3. Low-Density Lipoprotein Test Market Trends And Strategies

4. Low-Density Lipoprotein Test Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Low-Density Lipoprotein Test Growth Analysis And Strategic Analysis Framework

6. Low-Density Lipoprotein Test Market Segmentation

7. Low-Density Lipoprotein Test Market Regional And Country Analysis

8. Asia-Pacific Low-Density Lipoprotein Test Market

9. China Low-Density Lipoprotein Test Market

10. India Low-Density Lipoprotein Test Market

11. Japan Low-Density Lipoprotein Test Market

12. Australia Low-Density Lipoprotein Test Market

13. Indonesia Low-Density Lipoprotein Test Market

14. South Korea Low-Density Lipoprotein Test Market

15. Western Europe Low-Density Lipoprotein Test Market

16. UK Low-Density Lipoprotein Test Market

17. Germany Low-Density Lipoprotein Test Market

18. France Low-Density Lipoprotein Test Market

19. Italy Low-Density Lipoprotein Test Market

20. Spain Low-Density Lipoprotein Test Market

21. Eastern Europe Low-Density Lipoprotein Test Market

22. Russia Low-Density Lipoprotein Test Market

23. North America Low-Density Lipoprotein Test Market

24. USA Low-Density Lipoprotein Test Market

25. Canada Low-Density Lipoprotein Test Market

26. South America Low-Density Lipoprotein Test Market

27. Brazil Low-Density Lipoprotein Test Market

28. Middle East Low-Density Lipoprotein Test Market

29. Africa Low-Density Lipoprotein Test Market

30. Low-Density Lipoprotein Test Market Competitive Landscape And Company Profiles

31. Low-Density Lipoprotein Test Market Other Major And Innovative Companies

32. Global Low-Density Lipoprotein Test Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Low-Density Lipoprotein Test Market

34. Recent Developments In The Low-Density Lipoprotein Test Market

35. Low-Density Lipoprotein Test Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기